SSCRIPTURAclinical · decision · supportScriptura
Sign in
Patient sign inClinician sign in
Back to peptide rules

Tirzepatide

Regulatory status by US jurisdiction. Reviewed and signed by a clinician. Not a dosing guide, not legal advice, and not a device.

Scriptura flags, alerts, and informs. The prescribing clinician makes every decision.

Federal posture

  • FDA approved for a specific indication.
  • 503A bulks list: Never listed on the 503A bulks list.
  • DEA schedule: Not scheduled.

Status by jurisdiction

JurisdictionStatusVerified
AlabamaNo compound specific state restriction2026-07-22
AlaskaNo compound specific state restriction2026-07-22
ArizonaNo compound specific state restriction2026-07-22
ArkansasNo compound specific state restriction2026-07-22
CaliforniaNo compound specific state restriction2026-07-22
ColoradoNo compound specific state restriction2026-07-22
ConnecticutNo compound specific state restriction2026-07-22
DelawareNo compound specific state restriction2026-07-22
District of ColumbiaNo compound specific state restriction2026-07-22
FloridaNo compound specific state restriction2026-07-22
GeorgiaNo compound specific state restriction2026-07-22
HawaiiNo compound specific state restriction2026-07-22
IdahoNo compound specific state restriction2026-07-22
IllinoisNo compound specific state restriction2026-07-22
IndianaNo compound specific state restriction2026-07-22
IowaNo compound specific state restriction2026-07-22
KansasNo compound specific state restriction2026-07-22
KentuckyNo compound specific state restriction2026-07-22
LouisianaNo compound specific state restriction2026-07-22
MaineNo compound specific state restriction2026-07-22
MarylandNo compound specific state restriction2026-07-22
MassachusettsNo compound specific state restriction2026-07-22
MichiganNo compound specific state restriction2026-07-22
MinnesotaNo compound specific state restriction2026-07-22
MississippiNo compound specific state restriction2026-07-22
MissouriNo compound specific state restriction2026-07-22
MontanaNo compound specific state restriction2026-07-22
NebraskaNo compound specific state restriction2026-07-22
NevadaNo compound specific state restriction2026-07-22
New HampshireNo compound specific state restriction2026-07-22
New JerseyNo compound specific state restriction2026-07-22
New MexicoNo compound specific state restriction2026-07-22
New YorkNo compound specific state restriction2026-07-22
North CarolinaNo compound specific state restriction2026-07-22
North DakotaNo compound specific state restriction2026-07-22
OhioNo compound specific state restriction2026-07-22
OklahomaNo compound specific state restriction2026-07-22
OregonNo compound specific state restriction2026-07-22
PennsylvaniaNo compound specific state restriction2026-07-22
Puerto RicoNo compound specific state restriction2026-07-22
Rhode IslandNo compound specific state restriction2026-07-22
South CarolinaNo compound specific state restriction2026-07-22
South DakotaNo compound specific state restriction2026-07-22
TennesseeNo compound specific state restriction2026-07-22
TexasNo compound specific state restriction2026-07-22
UtahNo compound specific state restriction2026-07-22
VermontNo compound specific state restriction2026-07-22
VirginiaNo compound specific state restriction2026-07-22
WashingtonNo compound specific state restriction2026-07-22
West VirginiaNo compound specific state restriction2026-07-22
WisconsinNo compound specific state restriction2026-07-22
WyomingNo compound specific state restriction2026-07-22

The verified date is the date the reviewer confirmed the status against public sources. It is not a state board confirmation. The prescribing clinician owns the compliance decision.

Read the federal timeline for peptide compounding, July 2026.
Reviewed and signed
Clinical review: Sabrina Runbeck, MPH, MHS, PA-C, Clinical Director, Scriptura Health, on 2026-07-22.
Subject matter: Sabrina Runbeck, MPH, MHS, PA-C, Clinical Director, Scriptura Health, on 2026-07-22.
Verified against public sources on 2026-07-22.

Get Scriptura in your clinic

See how Scriptura pulls federal, state, and clinical sources into one reviewed view for prescribing clinicians. Book a live walkthrough, or get short updates when the rules move.

Reviewed by Sabrina Runbeck, MPH, MHS, PA-C, Clinical Director, Scriptura Health.

Tirzepatide regulatory status by US jurisdiction | Scriptura Health